Rothschild & Co Redburn Initiates Coverage on MiniMed Group (NASDAQ:MMED)

Posted by Brian Himes on Oct 13th, 2026

Research analysts at Rothschild & Co Redburn began coverage on shares of MiniMed Group (NASDAQ:MMED – Get Free Report) in a research report issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $30.00 price target on the stock. Rothschild & Co Redburn’s price objective suggests a potential upside of 59.57% from the stock’s current price.

Several other equities analysts also recently commented on MMED. Barclays began coverage on MiniMed Group in a research report on Wednesday, October 7th. They issued an “equal weight” rating and a $22.00 price objective on the stock. Bank of America lifted their target price on MiniMed Group from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Truist Financial started coverage on shares of MiniMed Group in a research note on Thursday, September 24th. They set a “buy” rating and a $29.00 target price for the company. Weiss Ratings upgraded shares of MiniMed Group from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, September 9th. Finally, Morgan Stanley upped their price target on shares of MiniMed Group from $19.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Fourteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Read Our Latest Report on MMED

MiniMed Group Stock Performance

MMED opened at $18.80 on Tuesday. The stock has a market cap of $5.29 billion and a price-to-earnings ratio of -27.65. The stock’s 50 day moving average price is $20.63 and its 200-day moving average price is $16.44. MiniMed Group has a one year low of $10.65 and a one year high of $24.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp bought a new stake in MiniMed Group during the 2nd quarter valued at $6,029,000. The Manufacturers Life Insurance Company purchased a new stake in shares of MiniMed Group in the 2nd quarter worth $185,000. WINTON GROUP Ltd purchased a new stake in shares of MiniMed Group in the 2nd quarter worth $273,000. Engineers Gate Manager LP bought a new position in shares of MiniMed Group during the 2nd quarter worth $513,000. Finally, Squarepoint Ops LLC bought a new position in shares of MiniMed Group during the 2nd quarter worth $403,000.

MiniMed Group Company Profile

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.